Slow Transit Constipation Clinical Trial
Official title:
Characterization of Intestinal Microbiota in Constipation Patients: Using 16S rRNA Gene Sequencing Analysis
Constipation is a frequent, chronic gastroenterological problem that has many varied
symptoms and thus has several clinical definitions. According to the Rome III criteria for
chronic constipation, almost 16% of all adults are affected by chronic constipation
worldwide, and it is more prevalent and symptomatic in women and elderly people. Slow
transit constipation (STC) is the major category and is characterized by a decreased rate of
colonic transit.
Recently, many researchers have focused on the relationship between intestinal microbiota
and constipation and have demonstrated that intestinal microbiota contribute to the
pathophysiology of functional gastrointestinal disorders.
Thus, there is a need for an improved understanding of gut microbiota composition in
constipation patients and for the potential role played by the gut microbiota in the
etiology of STC.To achieve this goal the investigators characterized and compared the
intestinal microbiota among carefully selected patients with constipation that were
clinically categorized based on Rome III criteria, and healthy controls using high
throughput pyrosequencing of the 16S rRNA gene and a conservative approach to detect
quantitative changes in the relative abundances of taxa.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | February 2017 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Chronic constipation according to Rome III criteria, defined as two or fewer spontaneous, complete bowel movements (SCBMs) per week for a minimum of 6 months; 2. Age > 18 years; 3. BMI: 18.5-25 kg/m2; 4. Slow colonic transit confirmed by colonic transit test (colonic transit time (CTT) > 48 hours); 5. Normal anorectal manometry, with no evidence of dyssynergia and confirmed ability to expel rectal balloon; 6. No radiographic evidence of functional (i.e. pelvic floor dyssynergia) or anatomical (i.e. significant rectocele and intussusception) impediment to the expulsion of the radio-opaque contrast; 7. Disease duration > 1 year; 8. Traditional treatment with dietary modification, laxatives (including osmotic and stimulant laxatives), and biofeedback tried over the past 6 months without success; Exclusion Criteria: 1. Bowel constipation due to innate factor (i.e. megacolon) or secondary interventions (i.e. drugs, endocrine, metabolic, neurologic or psychologic disorders); 2. History or evidence of gastrointestinal diseases (i.e. obstruction, cancer, inflammatory bowel diseases) ; 3. Previous abdominal surgery, except cholecystectomy, appendicectomy, tubal ligation and cesarean section; 4. Previous proctological or perianal surgery; 5. A constipation condition meeting the Rome III criteria for IBS or functional abdominal pain syndrome; 6. Pregnant or breast-feeding women; 7. Infection with enteric pathogen; 8. Usage of probiotics, prebiotics and/or synbiotics within the last month; 9. Usage of antibiotics and/or PPIs within the last 3 months; 10. Smoking or alcohol addiction within the last 3 months; |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
China | Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jinling Hospital, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fecal microbiota sequence | The fecal samples and isolated microbiota samples were frozen immediately and underwent DNA extraction using standard methods at BGI-Shenzhen | Within a week after enroll | Yes |
Secondary | Stool short-chain fatty acids (SCFAs) | The stool short-chain fatty acids (SCFAs) were extracted and quantitatively analysed by gas chromatography-mass spectrometry (GC-MS) | Within a week after enroll | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02844426 -
Effect of a Synbiotic on Symptoms of Patients With STC
|
Phase 2 | |
Recruiting |
NCT02526849 -
Efficacy and Safety of Fecal Microbiota Transplantation for Slow Transit Constipation
|
Phase 2 | |
Recruiting |
NCT05352074 -
STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation
|
N/A | |
Recruiting |
NCT02291354 -
Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation
|
Phase 2 | |
Active, not recruiting |
NCT02301221 -
Effect of Fecal Microbiota Transplantation in Slow Transit Constipation
|
Phase 2 | |
Active, not recruiting |
NCT05718505 -
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
|
N/A | |
Recruiting |
NCT02676388 -
Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation
|
Phase 2 |